Details of the Drug

General Information of Drug (ID: DMCBJSR)

Drug Name
Sunitinib
Synonyms
Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Gastrointestinal cancer 2C11 Approved [1], [2], [3]
Gastrointestinal stromal tumour 2B5B Approved [4]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 398.5
Topological Polar Surface Area (xlogp) 2.6
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Clearance
The apparent oral clearance of drug is 34-62 L/h [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 40 - 60 hours [6]
Metabolism
The drug is metabolized via the cytochrome P450 enzyme CYP3A4 [7]
Vd
The volume of distribution (Vd) of drug is 2230 L [5]
Chemical Identifiers
Formula
C22H27FN4O2
IUPAC Name
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Canonical SMILES
CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C
InChI
InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
InChIKey
WINHZLLDWRZWRT-ATVHPVEESA-N
Cross-matching ID
PubChem CID
5329102
ChEBI ID
CHEBI:38940
CAS Number
557795-19-4
DrugBank ID
DB01268
TTD ID
D0R0MW
VARIDT ID
DR00454
INTEDE ID
DR1519
ACDINA ID
D00646

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Modulator [2], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
RalBP1-associated Eps domain-containing protein 2 (RALBP1) DTYEM9B REPS2_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [14]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Gastrointestinal cancer
ICD Disease Classification 2C11
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor receptor 2 (KDR) DTT KDR 1.98E-01 0.11 0.2
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 9.45E-01 -5.34E-02 -9.01E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 9.69E-01 1.16E-03 3.56E-03
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 8.15E-01 6.20E-03 5.61E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sunitinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Sunitinib and Avapritinib. Gastrointestinal stromal tumour [2B5B] [74]
Coadministration of a Drug Treating the Disease Different from Sunitinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [75]
Metreleptin DM1NOEK Moderate Increased metabolism of Sunitinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [75]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Sunitinib and Insulin-glulisine. Acute diabete complication [5A2Y] [76]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Sunitinib and Insulin-aspart. Acute diabete complication [5A2Y] [77]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Sunitinib and Ivosidenib. Acute myeloid leukaemia [2A60] [78]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Midostaurin. Acute myeloid leukaemia [2A60] [79]
Arn-509 DMT81LZ Major Increased metabolism of Sunitinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [75]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Gilteritinib. Acute myeloid leukaemia [2A60] [80]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Oliceridine. Acute pain [MG31] [79]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Sunitinib and Dronedarone. Angina pectoris [BA40] [79]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Sunitinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [81]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Levalbuterol. Asthma [CA23] [82]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Pirbuterol. Asthma [CA23] [83]
Oritavancin DM28D05 Moderate Increased metabolism of Sunitinib caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [75]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Sunitinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [75]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Retigabine. Behcet disease [4A62] [79]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Sunitinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [84]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Eribulin. Breast cancer [2C60-2C6Y] [79]
Tucatinib DMBESUA Moderate Decreased metabolism of Sunitinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [75]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Bosutinib. Breast cancer [2C60-2C6Y] [74]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [85]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [83]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [82]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Indacaterol. Chronic obstructive pulmonary disease [CA22] [83]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Arformoterol. Chronic obstructive pulmonary disease [CA22] [83]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Probucol. Coronary atherosclerosis [BA80] [79]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Sunitinib and Pasireotide. Cushing syndrome [5A70] [79]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Osilodrostat. Cushing syndrome [5A70] [79]
Lumacaftor DMCLWDJ Major Increased metabolism of Sunitinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [75]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Deutetrabenazine. Dystonic disorder [8A02] [86]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Sunitinib and Ingrezza. Dystonic disorder [8A02] [87]
Cenobamate DMGOVHA Moderate Increased metabolism of Sunitinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Fosphenytoin DMOX3LB Major Increased metabolism of Sunitinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Rufinamide DMWE60C Moderate Increased metabolism of Sunitinib caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Sunitinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [75]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Cannabidiol. Epileptic encephalopathy [8A62] [74]
Tazemetostat DMWP1BH Moderate Increased metabolism of Sunitinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [75]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Solifenacin. Functional bladder disorder [GC50] [79]
Boceprevir DMBSHMF Moderate Decreased metabolism of Sunitinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [79]
Telaprevir DMMRV29 Moderate Decreased metabolism of Sunitinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [75]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [88]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Sunitinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [89]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Sunitinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Etravirine DMGV8QU Moderate Increased metabolism of Sunitinib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [79]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Sunitinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [90]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Sunitinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [79]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Sunitinib and BMS-201038. Hyper-lipoproteinaemia [5C80] [91]
Lesinurad DMUR64T Moderate Increased metabolism of Sunitinib caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [75]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Sunitinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [92]
Amobarbital DM0GQ8N Moderate Increased metabolism of Sunitinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [75]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [74]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Sunitinib and Phenolphthalein. Irritable bowel syndrome [DD91] [79]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Sunitinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [75]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Sunitinib and Crizotinib. Lung cancer [2C25] [93]
Brigatinib DM7W94S Moderate Increased metabolism of Sunitinib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [75]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Sunitinib and Ceritinib. Lung cancer [2C25] [79]
PF-06463922 DMKM7EW Moderate Increased metabolism of Sunitinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [75]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Sunitinib and Osimertinib. Lung cancer [2C25] [94]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Sunitinib and Selpercatinib. Lung cancer [2C25] [74]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Sunitinib and Lumefantrine. Malaria [1F40-1F45] [75]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Sunitinib and Hydroxychloroquine. Malaria [1F40-1F45] [95]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [74]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Idelalisib. Mature B-cell leukaemia [2A82] [96]
IPI-145 DMWA24P Moderate Decreased metabolism of Sunitinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [97]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Sunitinib and Vemurafenib. Melanoma [2C30] [79]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and LGX818. Melanoma [2C30] [98]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Sunitinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [75]
Exjade DMHPRWG Moderate Increased metabolism of Sunitinib caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [75]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Sunitinib and Panobinostat. Multiple myeloma [2A83] [99]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Sunitinib and Siponimod. Multiple sclerosis [8A40] [75]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Sunitinib and Fingolimod. Multiple sclerosis [8A40] [79]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Sunitinib and Ozanimod. Multiple sclerosis [8A40] [100]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Romidepsin. Mycosis fungoides [2B01] [79]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Sunitinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [74]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Sunitinib and Nilotinib. Myeloproliferative neoplasm [2A20] [79]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Lofexidine. Opioid use disorder [6C43] [79]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Rucaparib. Ovarian cancer [2C73] [79]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Triclabendazole. Parasitic worm infestation [1F90] [79]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Pimavanserin. Parkinsonism [8A00] [101]
Abametapir DM2RX0I Moderate Decreased metabolism of Sunitinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [102]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Sunitinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [103]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Sunitinib and Lefamulin. Pneumonia [CA40] [104]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Sunitinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [75]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Degarelix. Prostate cancer [2C82] [74]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Sunitinib and ABIRATERONE. Prostate cancer [2C82] [74]
Enzalutamide DMGL19D Major Increased metabolism of Sunitinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [75]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Relugolix. Prostate cancer [2C82] [74]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Levomepromazine. Psychotic disorder [6A20-6A25] [79]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Sunitinib and Iloperidone. Schizophrenia [6A20] [79]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Sunitinib and Amisulpride. Schizophrenia [6A20] [105]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Asenapine. Schizophrenia [6A20] [79]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Sunitinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [75]
Larotrectinib DM26CQR Moderate Decreased metabolism of Sunitinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [75]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Sunitinib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [74]
Armodafinil DMGB035 Moderate Increased metabolism of Sunitinib caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [75]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Sunitinib and LEE011. Solid tumour/cancer [2A00-2F9Z] [79]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Sunitinib and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [79]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [74]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Pitolisant. Somnolence [MG42] [79]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [79]
Fostamatinib DM6AUHV Moderate Decreased clearance of Sunitinib due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [106]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Sunitinib and Lenvatinib. Thyroid cancer [2D10] [79]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Sunitinib and Cabozantinib. Thyroid cancer [2D10] [74]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Sunitinib and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [76]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Sunitinib and Insulin degludec. Type-1/2 diabete [5A10-5A11] [76]
Elagolix DMB2C0E Moderate Increased metabolism of Sunitinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [75]
⏷ Show the Full List of 108 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium hydroxide E00234 14798 Alkalizing agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sunitinib 25 mg capsule 25 mg Oral Capsule Oral
Sunitinib 37.5 mg capsule 37.5 mg Oral Capsule Oral
Sunitinib 50 mg capsule 50 mg Oral Capsule Oral
Sunitinib 12.5 mg capsule 12.5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5713).
2 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
3 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
4 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37.
9 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
10 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
11 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
12 Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9.
13 In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
14 Drug Interactions Flockhart Table
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
25 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
26 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
27 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
28 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
29 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
30 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
31 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
32 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
33 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
34 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
35 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
36 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
37 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
38 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
39 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
40 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
41 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
42 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
43 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
44 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
45 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
46 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
47 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
48 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
49 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
50 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
51 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
52 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
53 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
54 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
55 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
56 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
57 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
58 FDA Drug Development and Drug Interactions
59 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
60 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
61 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
62 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
63 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
64 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
65 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
66 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
67 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
68 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
69 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
70 Clinical pipeline report, company report or official report of Exelixis (2011).
71 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
72 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
73 YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80.
74 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
75 Cerner Multum, Inc. "Australian Product Information.".
76 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
77 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
78 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
79 Canadian Pharmacists Association.
80 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
81 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
82 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
83 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
84 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
85 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
86 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
87 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
88 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
89 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
90 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
91 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
92 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
93 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
94 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
95 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
96 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
97 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
98 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
99 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
100 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
101 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
102 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
103 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
104 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
105 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
106 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.